iPSC– tag –
-
Liv Hospital Pioneers iPSC-Driven 3D Bioprinting and Organoid Development, Reshaping Organ Transplantation
Liv Hospital Turkey Overview Liv Hospital is at the forefront of research highlighting the pivotal role of induced pluripotent stem cell (iPSC) lines in advancing 3D bioprinting and organoid development. These initiatives aim to engineer... -
BioInformant Details 2026 iPSC-Derived Cell Therapeutics Pipeline: Key Players Accelerate Clinical Development for Parkinson’s, Heart Failure, Cancer, and More
BioInformant USA Overview BioInformant's comprehensive report outlines the 2026 pipeline for iPSC-derived cell therapeutics, highlighting progress from key companies like Fate Therapeutics, BlueRock Therapeutics, FUJIFILM Cellular Dynami... -
Precision Gene Editing with Adenine Base Editors Restores Muscle Function in Childhood FSHD Model, Advancing Gene Therapy
bioRxiv Australia Overview This study presents a novel therapeutic strategy for childhood-onset Facioscapulohumeral Muscular Dystrophy (FSHD), an intractable genetic disorder. Researchers leveraged an iPSC-derived skeletal muscle model t... -
Century Therapeutics Pivots iPSC Platform to Type 1 Diabetes Beta Cell Therapy, Targeting 2025 IND with Off-the-Shelf Approach
Century Therapeutics USA Overview Century Therapeutics has announced a strategic realignment of its induced pluripotent stem cell (iPSC) platform, now exclusively dedicated to developing beta islet cell therapy for Type 1 Diabetes. The c... -
iPSC-Derived Microglia-like Cells Reveal Protocol-Specific Transcriptomes and Potent Glioma Phagocytosis, Advancing Brain Tumor Research
bioRxiv USA Overview Human induced pluripotent stem cell (iPSC)-derived microglia-like cells (iMG) are emerging as critical tools for understanding human microglia function and the brain tumor microenvironment. A comprehensive study anal... -
Hopstem’s iPSC-Derived Neural Progenitor Cell hNPC01 Receives FDA IND Clearance and Fast Track Designation for Stroke and Traumatic Brain Injury
AllSci USA Overview Hopstem Biotechnology announced that its allogeneic iPSC-derived forebrain neural progenitor cell therapy, hNPC01, received both IND clearance and Fast Track designation from the U.S. FDA for treating chronic motor de... -
Advanced CAR-T/NK Therapies for Solid Tumors: iPSC-Derived CAR-NK Cells Show Promise in Efficacy and Safety
Oncodaily Global Overview In solid tumor treatment, IL-15 armed GPC3 CAR-T cells demonstrated promising early data, with cytokine release syndrome (CRS) managed by an inducible caspase-9 switch. Notably, iPSC-derived IL-15 incorporated C... -
iPSC-Derived Cell Therapy Pipeline Expands: Hopstem Leads Chinese Market with Neurological and Immunological Disease Applications
BioInformant USA Overview The iPSC-derived cell therapy pipeline is rapidly expanding from disease modeling to clinical applications across cardiovascular, neurological, metabolic, ocular, and oncological diseases. Hopstem Biotechnology ... -
First-in-Human Diabetes Cell Therapy Shows Promising Initial Clinical Data
The Medicine Maker UK Overview The world's first human diabetes cell therapy has reportedly shown promising initial data in clinical trials. This therapy holds the potential to reduce insulin dependency in Type 1 diabetes patients by rep... -
Long-Term Safety of iPS Cell Therapy for Spinal Cord Injury Confirmed in Japan
Nippon.com Japan Overview Long-term safety has been confirmed in Japan for a spinal cord injury treatment involving the transplantation of neural progenitor cells derived from induced pluripotent stem cells (iPS cells). A clinical trial ...
